A Study to Test the Efficacy of the HBV Vaccine and to Look at the Prevalence of HBV Infection
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The prevalence of Hepatitis B core antigen in the Thai population is about 70 %, no data of isolated Hepatitis B core antigen is reported. Hepatitis B core antigen is observed in 10%-20% of individuals from low endemic areas of HBV infection. However, this prevalence of isolated antiHBc would be higher in endemic area of HBV infection. There is conflicting data of occult HBV infection in HIV infected patients. In Thailand, perinatal transmission is the main route of transmission which is different from developed countries. Therefore, isolated antiHBc in Thai people has longer duration than low prevalence regions. Moreover, HBV genotype C and B is common in this region. If the HBV vaccination could eliminate an occult HBV infection in these individuals, the liver related mortality might be reduced. The prevalence and clinical importance of isolated antiHBc in Thai have not been investigated yet. There is also limited data of HBV vaccine response in this setting.
| Condition | Intervention |
|---|---|
|
Hepatitis B Virus |
Biological: HBV vaccine |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | The Efficacy of HBV Vaccine Response and Prevalence of Occult HBV Infection in Isolated Anti HBc Between HIV Infected and HIV Un-infected Thai Patients |
- HBV DNA in HIV-infected patients presenting with a serological pattern of isolated anti-HBcAg compare to non HIV patients with isolated antiHBc [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- antiHBs titer after 2 month of third dose of HBV vaccine in both 2 groups [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- liver function test after HAART in HIV patients compare between negative and positive HBV DNA [ Time Frame: 1 year ] [ Designated as safety issue: No ]
- 3TC resistant after 3TC containing HAART in HIV patients with detectable HBV DNA prior treatment [ Time Frame: 1 year ] [ Designated as safety issue: No ]
| Enrollment: | 200 |
| Study Start Date: | December 2006 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
HBV vaccine
|
Biological: HBV vaccine
HBV vaccine 3 doses at month 0, 1, and 6
|
Detailed Description:
The prevalence of the Hepatitis B core antigen (anti-HBc)in the Thai population is about 70 %. No data of isolated anti-HBc is reported. Anti-HBc antigen is observed in 10%-20% of individuals from low endemic areas of HBV infection. The prevalence of isolated antiHBc antigen is expected to be higher in endemic areas of HBV infection. There is conflicting data of occult HBV infection in HIV-infected patients. In Thailand, perinatal transmission is the main route of HBV transmission, different from developed countries. Therefore, isolated anti-HBc in Thai people has longer duration than low prevalence regions. Moreover, HBV genotype C and B is common in this region. HBV genotype C is correlated with more cirrhosis and hepatoma than genotype B. A study from Taiwan demonstrated that HBV DNA > 100,000 copies/ml is correlated with cirrhosis and hepatoma. Sustained reduction of HBV replication lowers the risk of hepatoma in HBV related cirrhosis. If the HBV vaccination could eliminate an occult HBV infection in these individuals, the liver related mortality will be reduced.
The prevalence and its clinical importance of isolated anti-HBc in the Thai population has not been investigated yet. There is also limited data of HBV vaccine response in this setting.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- HIV-infected adults followed at HIV-NAT and HIV-NAT affiliated hospitals and Un-infected HIV adults followed at chulalongkorn hospital and blood bank
- AntiHBc positive without HBsAg and antiHBs
- Written inform consent
Exclusion Criteria:
- Patients receiving, or with an anticipated need to receive, any concomitant medications with the potential to decrease the response to HBV vaccine such as long term steroid user, chemotherapy, cancer
Contacts and Locations| Thailand | |
| HIV-NAT Thai Red Cross AIDS Research Center | |
| Bangkok, Thailand, 10330 | |
| Principal Investigator: | Anchalee Avihingsanon, MD | HIV-NAT, Thai Red Cross AIDS Research Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | Kiat Ruxrungtham, HIV-NAT |
| ClinicalTrials.gov Identifier: | NCT00476411 History of Changes |
| Other Study ID Numbers: | HIV-NAT 036 |
| Study First Received: | May 20, 2007 |
| Last Updated: | June 4, 2010 |
| Health Authority: | Thailand: Food and Drug Administration |
Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
|
isolated HBc HBV vaccine response occult HBV in isolated antiHBC compared HIV to non HIV |
Additional relevant MeSH terms:
|
Hepatitis Hepatitis A Hepatitis B Liver Diseases Digestive System Diseases Hepatitis, Viral, Human |
Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Hepadnaviridae Infections DNA Virus Infections |
ClinicalTrials.gov processed this record on June 17, 2013